PHA 568487CAS# 527680-57-5 |
- SB 203580
Catalog No.:BCC3663
CAS No.:152121-47-6
- BIRB 796 (Doramapimod)
Catalog No.:BCC2535
CAS No.:285983-48-4
- LY2228820
Catalog No.:BCC2528
CAS No.:862507-23-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 527680-57-5 | SDF | Download SDF |
| PubChem ID | 56972212 | Appearance | Powder |
| Formula | C20H24N2O7 | M.Wt | 404.41 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 100 mM in water and to 100 mM in DMSO | ||
| Chemical Name | N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-2,3-dihydro-1,4-benzodioxine-6-carboxamide;(E)-but-2-enedioic acid | ||
| SMILES | C1CN2CCC1C(C2)NC(=O)C3=CC4=C(C=C3)OCCO4.C(=CC(=O)O)C(=O)O | ||
| Standard InChIKey | QYQZUGYJVHHHEE-QDSMGTAFSA-N | ||
| Standard InChI | InChI=1S/C16H20N2O3.C4H4O4/c19-16(17-13-10-18-5-3-11(13)4-6-18)12-1-2-14-15(9-12)21-8-7-20-14;5-3(6)1-2-4(7)8/h1-2,9,11,13H,3-8,10H2,(H,17,19);1-2H,(H,5,6)(H,7,8)/b;2-1+/t13-;/m0./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Agonist of the α7 nicotinic acetylcholine receptor (Ki values are 44 and 2800 for α7 and 5-HT3 respectively, IC50 values are > 100 μM for α3β4 and α1β1δγ respectively, and % inhibition is < 1 and 5% for α4β2 and hERG respectively). Orally active and brain penetrant. |
PHA 568487 Dilution Calculator
PHA 568487 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.4727 mL | 12.3637 mL | 24.7274 mL | 49.4548 mL | 61.8185 mL |
| 5 mM | 0.4945 mL | 2.4727 mL | 4.9455 mL | 9.891 mL | 12.3637 mL |
| 10 mM | 0.2473 mL | 1.2364 mL | 2.4727 mL | 4.9455 mL | 6.1818 mL |
| 50 mM | 0.0495 mL | 0.2473 mL | 0.4945 mL | 0.9891 mL | 1.2364 mL |
| 100 mM | 0.0247 mL | 0.1236 mL | 0.2473 mL | 0.4945 mL | 0.6182 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Medicarpin 3-O-glucoside
Catalog No.:BCN7773
CAS No.:52766-70-8
- beta-Asarone
Catalog No.:BCN5685
CAS No.:5273-86-9
- Isoelemicin
Catalog No.:BCN4760
CAS No.:5273-85-8
- Scillascillin
Catalog No.:BCN5684
CAS No.:52706-07-7
- Ginsenoside Rd
Catalog No.:BCN1074
CAS No.:52705-93-8
- Herbacetin
Catalog No.:BCN1268
CAS No.:527-95-7
- Azomycin
Catalog No.:BCC5315
CAS No.:527-73-1
- Sodium Gluconate
Catalog No.:BCC4721
CAS No.:527-07-1
- D-Penylalaninol
Catalog No.:BCC2715
CAS No.:5267-64-1
- A23187, free acid
Catalog No.:BCC6980
CAS No.:52665-69-7
- Kirenol
Catalog No.:BCN5682
CAS No.:52659-56-0
- Anisodine
Catalog No.:BCN1868
CAS No.:52646-92-1
- H-D-Phe(3,4-DiCl)-OH
Catalog No.:BCC3179
CAS No.:52794-98-6
- H-Phe(3,4-DiCl)-OH
Catalog No.:BCC3178
CAS No.:52794-99-7
- Magnolol
Catalog No.:BCN5687
CAS No.:528-43-8
- Fisetin
Catalog No.:BCN5024
CAS No.:528-48-3
- Delphinidin chloride
Catalog No.:BCN3015
CAS No.:528-53-0
- Cyanidin Chloride
Catalog No.:BCN1231
CAS No.:528-58-5
- (±)-Galgravin
Catalog No.:BCN8283
CAS No.:528-63-2
- Isobavachromene
Catalog No.:BCN3192
CAS No.:52801-22-6
- L-Quisqualic acid
Catalog No.:BCC6568
CAS No.:52809-07-1
- Dalbergiphenol
Catalog No.:BCN7451
CAS No.:52811-31-1
- Cearoin
Catalog No.:BCN7772
CAS No.:52811-37-7
- Olean-12-ene-3,11-diol
Catalog No.:BCN5686
CAS No.:5282-14-4
Donepezil and the alpha-7 agonist PHA 568487, but not risperidone, ameliorate spatial memory deficits in a subchronic MK-801 mouse model of cognitive impairment in schizophrenia.[Pubmed:25036424]
Behav Brain Res. 2014 Oct 1;272:248-51.
Cognitive impairment associated with schizophrenia (CIAS) is an important etiological feature of this disorder with implications for symptom severity and quality of life. Acute N-methyl-d-aspartate receptor (NMDAR) blockade using MK-801, a non-competitive antagonist to NMDARs, is assumed to produce temporary cognitive impairments in mice similar to those seen in schizophrenia patients. Less is known, however, about the effects of subchronic MK-801 administration on cognition. In the current study, twenty-eight male C57/BL6 mice received a daily dose of MK-801 (0.1mg/kg, i.p.) for seven days. Spatial memory was assessed using an object location task prior to MK-801 administration as well as at multiple time points after the treatment. Subchronic treatment with MK-801 caused lasting memory deficits, which were ameliorated by acute doses of an acetylcholinesterase inhibitor (donepezil) and an alpha-7 nicotinic agonist (PHA 568487), but were unaffected by acute administration of the atypical antipsychotic risperidone. Subchronic administration of MK-801 may lend this pharmaceutical model increased face validity, while its resemblance to prodromal schizophrenia makes it suitable for screening new CIAS treatments.
Multiple species metabolism of PHA-568487, a selective alpha 7 nicotinic acetylcholine receptor agonist.[Pubmed:20642449]
Drug Metab Lett. 2010 Aug;4(3):162-72.
The quinuclidine PHA-0568487(1) is an agonist of the alpha 7 nicotinic acetylcholine receptor that was designed to mitigate the bioactivation associated with the core scaffold and subsequently remove associated liabilities with in vivo tolerability. The drug metabolites of 1 in nonclinical species were identified in plasma and urine of rats, dogs and monkeys receiving oral administrations of 1. The in vitro biotransformation of 1 was subsequently investigated in multiple species employing cryopreserved hepatocytes, hepatic subcellular fractions and recombinantly-expressed human P450 enzymes. In addition, in vitro metabolism of synthetically prepared metabolite precursors were instrumental in the elucidation of several secondary metabolites. The results indicated that the principal biotransformation of 1 was oxidation of the benzo[1,4]dioxane moiety (M8, M10) followed by subsequent oxidation to a range of secondary metabolites (M1-7, M9, M11, M13-15, and M17-18). The carboxylic acids M1 and M2 resulting from the oxidative cleavage of the dioxane ring were the principal metabolites observed in the plasma, urine and hepatocyte incubations across all species (M1 & M2). Quinuclidine oxidation was another pathway of importance, yielding an N-oxide (M12) which was also observed in all species.P450 2D6 and FMO1 catalyze the oxidation of the quinuclidine nitrogen. The N oxidation of the quinuclidine moiety is consistent with previously published accounts of this scaffold's metabolism and, interestingly, may implicate the uncommon quinuclidine moiety as an entity directing the metabolism of this scaffold (e.g., 1) via FMO1 and P450 2D6 oxidation.
Design, synthesis, structure-activity relationship, and in vivo activity of azabicyclic aryl amides as alpha7 nicotinic acetylcholine receptor agonists.[Pubmed:17011782]
Bioorg Med Chem. 2006 Dec 15;14(24):8219-48.
A novel set of azabicyclic aryl amides have been identified as potent and selective agonists of the alpha7 nAChR. A two-pronged approach was taken to improve the potential hERG liability of previously disclosed alpha7 nAChR agonist, PNU-282,987, while maintaining the compound's other desirable pharmacological properties. The first approach involved further exploration of the aryl carboxylic acid fragment of PNU-282,987, while the second approach focused on modification of the azabicyclic amine portion of PNU-282,987. The best compounds from each series are characterized by rapid brain penetration, good oral bioavailability in rat, and demonstrate in vivo efficacy in a rat P50 auditory sensory gating assay. At least one analog from each series (1h, 1o, 2a, 9a, and 18a) shows an improved hERG safety profile over PNU-282,987.
